JNJaclynne H. Nader

Jaclynne H. Nader

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaclynne H. Nader has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Landscape of phase 1 clinical trials for minors with cancer in the United States

    by Jaclynne H. Nader, Dylan V. Neel, David S. Shulman, Clement Ma, Florence Bourgeois, Steven G. DuBois

    Objectives: Understanding trends in characteristics of early phase trials that allow minors with cancer to participate may inform additional efforts to improve cancer drug development for young people.Methods: We accessed data for oncology phase 1 or phase 1/2 trials in the United States from ClinicalTrials.gov with lower age bound for eligibility P ≤ .02). No other temporal trends were seen. The median times from first‐in‐adult to first‐in‐pediatric for monotherapy and combination trials were 5.7 and 3.3 years, respectively.Conclusion: The paucity of clear temporal trends highlights the need for innovation in early drug development for young people. Our analysis serves as a benchmark against which to evaluate initiatives to improve pediatric cancer drug development.